Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-09-25

Clinical Trial Update: A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer was terminated, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sprycel (dasatinib)

Snippet

Sponsor: Brown University | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2013-09-25